Ocular Therapeutix公司 OCUL 深 沪
等待开盘 04-03 09:30:00 美东时间
8.49
+0.160
+1.92%
华盛通- 最 高8.73
- 今 开8.09
- 成交量 437.40万股
- 最 低 8.09
- 昨 收 8.33
- 总市值 18.48亿
- 52周最高 16.44
- 市盈率 静 --
- 换手率 2.01%
- 52周最低 6.2301
- 委 比 42.00%
- 总股本 2.18亿
- 历史最高 44.19
- 量 比 1.19
- 振 幅 7.68%
- 历史最低 1.995
- 每 手 1
- 风险率 2.09%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Ocular Therapeutix to present additional SOL-1 Phase 3 AXPAXLI data at April conferences
Ocular Therapeutix to present additional SOL-1 Phase 3 AXPAXLI data at April conferences Ocular Therapeutix will present additional SOL-1 Phase 3 superiority trial data and analyses for AXPAXLI (OTX-TKI) in wet age-related macular degeneration at Vit-Buckle Society annual meeting on April 9-11, 2026
04-01 19:07
EyePoint Files Lawsuit Against Ocular Therapeutix Alleging Defamation And Misleading Claims Over DURAVYU Clinical Results
On March 20, 2026, EyePoint, Inc. (the "Company") filed a complaint against Ocular Therapeutix, Inc. (the "Defendant") in the Middlesex County Superior Court for the Commonwealth of Massachusetts (the "Complaint"). The
03-21 04:39
美股大行评级 | 绩后暴跌超22%，MongoDB遭14家大行集团下调目标价；挪威邮轮、阿莎娜、Quantum Computing等也遭大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持NRX Pharmaceuticals"买入"评级，目标价从40美元升至45美元；RBC Capital：维持NUVATION BIO"跑赢大市"评级，目标价从12美元升至13美元
03-04 10:22
GE Aerospace To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Tuesday
Benzinga's top Wall Street analysts changed outlook on these names: AVAV cut to $290, OCUL raised to $28, MDB cut to $260, RIOT cut to $23, DAVE raised to $295, NTST raised to $22, U raised to $19, TREE cut to $290.
03-03 21:37
Clear Street Maintains Buy on Ocular Therapeutix, Raises Price Target to $28
Clear Street analyst Bill Maughan maintains Ocular Therapeutix (NASDAQ:OCUL) with a Buy and raises the price target from $21 to $28.
03-03 18:06
美股牛股 | 英伟达40亿美元押注光通信！应用光电大涨超21%；BATL暴涨超113%
英伟达40亿美元押注光通信！应用光电大涨超21%；美伊冲突点燃“油气”市场，BATL股价暴涨超113%>>
03-03 16:03
Richard L. Lindstrom MD Acquires Ocular Therapeutix Common Shares
Richard L. Lindstrom MD Acquires Ocular Therapeutix Common Shares Richard L. Lindstrom, M.D., a beneficial owner of Ocular Therapeutix Inc., reported an acquisition of common shares of the company. The full filing can be accessed through the link below. Disclaimer: This news brief was created by Pub
02-25 07:13
Ocular Therapeutix To Reveal SOL-1 Superiority Trial Results For Wet AMD Treatment At Macula Society Symposium
Ocular to present detailed SOL-1 data at the 49th Macula Society Annual Meeting on Friday, February 27, 2026, starting at 1:00 PM PT (4:00 PM ET)Company to host an investor webcast on Monday, March 2, 2026, at 7:30 AM ET
02-23 20:05
Ocular Therapeutix to Present Detailed SOL-1 Data at Macula Society Annual Meeting and Host Investor Webcast
Ocular Therapeutix to Present Detailed SOL-1 Data at Macula Society Annual Meeting and Host Investor Webcast Ocular Therapeutix Inc. will present detailed results from its SOL-1 Phase 3 superiority trial of AXPAXLI (OTX-TKI) for wet age-related macular degeneration at the 49th Macula Society Annual
02-23 20:02
美股大行评级 | 潜在涨幅214.14%！HC Wainwright & Co.：Ardelyx获机构升目标价至18美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Ardelyx"买入"评级，目标价从10美元升至18美元；Truist Securities：维持Praxis Precision Medicine"买入"评级，目标价从500美元升至700美元
02-23 08:56
